Abstract:Interleukin (IL)-15 is a promising immunotherapeutic cytokine for cancer treatment because it can stimulate the proliferation and cytotoxicity of CD8+ T lymphocytes and nature killer (NK) cells, similar to the action of IL-2, which has been used to treat metastatic melanoma and renal cancer. IL-15 may have improved pharmacologic properties over IL-2 because it doesn't cause vascular leak syndrome or stimulate regulatory T cells. However, IL-15 is difficult to express as a stable soluble protein and has a short half-life in vitro and in vivo. To solve the problem, we designed an IL-15 ultralong CDR3 humanized bovine antibody fusion. Bovine ultralong CDR3 antibodies have a unique "stalk and knob" structure in which two antiparallel β-strands support a disulfide bonded knob protruding out of the antibody surface and forms a mini antigen binding domain. By replacing the knob domain with IL-15, we have created a chimeric CDR3-IL-15 IgG which functions as IL-15 in vitro and in vivo but can be easily produced in mammalian cells with increased stability. Thus, the CDR3 can stabilize IL-15 in the absence of its high affinity receptor α (Rα) chain. Furthermore, as IL-15 utilizes Rα for increased trans signaling to the receptor β and γ subunits, one variant candidate (CDR3-IL-15_Rα) was produced by co-expressing Rα sushi domain with the chimeric IgG. Both constructs have been demonstrated to be highly active in stimulating proliferation of NK cells and CD8+ T cells in vitro as well as in stimulating proliferation of NK cells and CD8+ T cells in rats and non-human primates (NHP). Although the CDR3-IL-15_Rα exhibited higher in vitro signaling activity than CDR3-IL-15, both were equally potent in stimulating the proliferation of NK cells and CD4+ and CD8+ T cells in NHP without any immunogenicity detected. Moreover, in vivo studies in NHP indicated that CDR3-IL-15 acted faster than CDR3-IL-15_Rα in stimulating the proliferation of these lymphocytes. CDR3-IL-15 is the first thermodynamically stabilized variant of IL-15 produced in the absence of its Rα chain, is highly active in vivo, and has multiple potential cancer applications as an T and NK cell stimulating agent. Citation Format: Ruiqi Huang, Duncan McGregor, Vaughn Smider. Ultralong CDR3 engineered interleukin-15 antibody fusion for T and NK cell expansion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5811.

Use of the SUMO Expression System to Efficiently Express the Soluble Human Interleukin-15 and the Activity Study

Activity of Recombinant Human Interleukin-15 Against Tumor Recurrence and Metastasis in Mice

Soluble expression, rapid purification, and characterization of human interleukin-24 (IL-24) using a MBP-SUMO dual fusion system in Escherichia coli

Utilization of SUMO Expressing Vector to Express Human Interleukin-17 and Studying of Its Bioactivity

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives

Recombinant human interleukin 15 long peptide fragment and production method thereof

Expression, purification, and biological characterization of recombinant human interleukin-31 protein

Development of a Recombinant Human IL-15·sIL-15Rα/Fc Superagonist with Improved Half-Life and Its Antitumor Activity Alone or in Combination with PD-1 Blockade in Mouse Model

[Purification of Fusion Protein HSA/IL1ra and Its Bioactivity].

Purification and bioactiveity detection of recombinant human interleukin 17

Clinical Manufacturing of Recombinant Human Interleukin 15. I. Production Cell Line Development and Protein Expression in E. Coli with Stop Codon Optimization.

High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: a Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four Α-Helices in a Bundle.

Soluble expression of recombinant human interleukin-2 in Escherichia coli and its facile production

Soluble Expression and Purification of Recombinant Human Interleukin-21 in Escherichia Coli

SUMO-fusion and autoinduction-based combinatorial approach for enhanced production of bioactive human interleukin-24 in Escherichia coli

A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy

Abstract 5811: Ultralong CDR3 engineered interleukin-15 antibody fusion for T and NK cell expansion

Soluble expression of human insulin-like growth factor-1 with the assistance of SUMO fusion partner

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

Purification and Characterization of Non-Fusion Recombinant Human Interleukin-18 Expressed in E. Coli